Century Therapeutics (NASDAQ:IPSC – Get Rating)‘s stock had its “buy” rating reiterated by stock analysts at EF Hutton Acquisition Co. I in a research note issued to investors on Monday, Benzinga reports. They currently have a $16.00 price target on the stock. EF Hutton Acquisition Co. I’s price objective would suggest a potential upside of 419.48% from the stock’s previous close.

Several other research firms have also issued reports on IPSC. Bank of America dropped their price objective on Century Therapeutics from $23.00 to $20.00 in a research note on Friday, March 17th. HC Wainwright  reissued a “buy” rating and set a $17.00 price objective on shares of Century Therapeutics in a research note on Thursday, April 13th. Piper Sandler dropped their price objective on Century Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, January 6th. SVB Leerink dropped their price objective on Century Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, January 6th. Finally, Chardan Capital  reissued a “buy” rating and set a $19.00 price objective on shares of Century Therapeutics in a research note on Wednesday, March 22nd. One equities research analyst  has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Century Therapeutics stock opened at $3.08 on Monday. The firm has a market capitalization of $182.24 million, a P/E ratio of -1.35 and a beta of 0.60. Century Therapeutics has a one year low of $2.81 and a one year high of $14.00. The business has a fifty day moving average price of $3.96 and a 200-day moving average price of $6.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.72 and a quick ratio of 10.72.

In related news, insider Luis Borges sold 15,597 shares of the business’s stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $3.55, for a total transaction of $55,369.35. Following the transaction, the insider now owns 249,083 shares in the company, valued at approximately $884,244.65. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own  10.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of IPSC. Tower Research Capital LLC TRC boosted its position in  Century Therapeutics by 27.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock valued at $41,000 after acquiring an additional 904 shares in the last quarter.  Barclays PLC boosted its position in shares of  Century Therapeutics by 533.3% in the 4th quarter. Barclays PLC now owns 5,408 shares of the company’s stock worth $28,000 after purchasing an additional 4,554 shares in the last quarter.  UBS Group AG bought a new stake in shares of  Century Therapeutics in the 4th quarter worth approximately $28,000.  Allspring Global Investments Holdings LLC bought a new stake in shares of  Century Therapeutics in the 4th quarter worth approximately $41,000.  Finally, American International Group Inc. boosted its position in shares of  Century Therapeutics by 37.1% in the 1st quarter. American International Group Inc. now owns 8,604 shares of the company’s stock worth $108,000 after purchasing an additional 2,328 shares in the last quarter. Hedge funds and other institutional investors own  35.81% of the company’s stock.

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.